The Effects Study of Isoniazid Conjugated Multi-Wall Carbon Nanotubes Nanofluid on Mycobacterium tuberculosis
Received 27 February 2020
Accepted for publication 28 July 2020
Published 13 August 2020 Volume 2020:15 Pages 5901—5909
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Anderson Oliveira Lobo
Shahab Zomorodbakhsh,1 Yasamin Abbasian,2 Maryam Naghinejad,3 Mojgan Sheikhpour3,4
1Department of Chemistry, Mahshahr Branch, Islamic Azad University, Mahshahr, Iran; 2Faculty of Pharmacy and Pharmaceutical Sciences, Islamic Azad University, Tehran, Iran; 3Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran; 4Microbiology Research Center, Pasteur Institute of Iran, Tehran, Iran
Correspondence: Mojgan Sheikhpour Tel +989122969712
Fax +98 21 64112313
Email [email protected]
Background: Tuberculosis (TB) has always been recognized as one of the fatal infectious diseases, which is caused by Mycobacterium tuberculosis (M.tb). Isonicotinic acid hydrazide or isoniazid (INH) is one of the most commonly utilized drugs in the treatment of TB. Patients need to take 300 mg daily of INH for 6 months in combination with another anti-TB drug and tolerate several side effects of INH. On the other hand, the emergence of resistant strains of anti-TB antibiotics is one of the major problems in the treatment of this disease. So, antimicrobial drug delivery by nanofluids could improve the efficacy, and reduce the adverse effects of antimicrobial drugs. The purpose of this study was to perform a novel method to synthesize INH-conjugated multi-wall carbon nanotubes (MWCNTs) for more effective drug delivery, as well as, TB treatment.
Methods: INH-conjugated functionalized MWCNTs were prepared, using a reflux system. The characterization of the obtained nano-drug was performed by the elemental analyses of total nitrogen, hydrogen, carbon and sulfur (CHNS), Raman spectroscopy, Fourier transform infrared (FTIR), transmission electron microscopy (TEM), and scanning electron microscopy (SEM) methods. The nanofluid of nano-drug was prepared by the ultrasonic method, and the related antibacterial effect studies were carried out on the two strains of M.tb.
Results: The antimicrobial effect of INH-conjugated MWCNTs was found to be much better at low concentrations than the pure drug in all of the strains.
Conclusion: Since one of the main antimicrobial mechanisms of MWCNTs is through the destruction of the bacterial cell wall, in addition to its antimicrobial effects, it increased the drug delivery of INH at lower doses compared to drug alone. So, the nanofluid, containing INH-conjugated MWCNTs, had a better lethal effect on a variety of M.tb strains than that of the drug alone.
Keywords: isoniazid, multi-wall carbon nanotubes, Mycobacterium tuberculosis, nano-drug, nanofluid
Tuberculosis (TB) has been illustrated as one of the most lethal infectious diseases in humans, which is caused by Mycobacterium tuberculosis (M.tb). Despite the ability of this pathogen to infect different parts of the body, the lungs are distinguished to be the most susceptible. According to the World Health Organization (WHO), about 10 million people are suffered from TB all over the world, each year.1,2 Isoniazid or isonicotinic acid hydrazide (INH) was mentioned as one of the common drugs used in treating the infectious parts of TB. Plenty of people are healed with this safe and cost-effective drug, which was introduced in 1952, despite creating liver problems.3,4 Typically, a daily administration of about 300 mg of INH was prescribed for six months with other effective medications. However, this consumption had side effects such as liver poisoning, jaundice, acute hepatic failure, and reduced blood pressure.5 Although TB is not a chronic disease, several drugs such as INH and rifampin are used for 4 to 7 months as well as pyrazinamide for eight weeks.6,7 Furthermore, ethambutol, streptomycin, and piperine were also demonstrated as effective drugs toward TB.8 Unfortunately, the existence of various infections in humans has made the pathogens more resistant to antibiotics such as INH. INH is used as the first-line drug to treat this infection, and M.tb inhA, ahpC, and fabD mutational genes are the common targets of this drug.9 On the other hand, chemotherapy has been the most common method to cure TB, by its advantages and side effects. Nano drug delivery system is an emerging technique to deliver multiple drugs, in a controllable release, lower systematic toxicity, and high drug bioavailability condition, compared to chemotherapy. So, researchers successfully used and confirmed several nano vehicles for sustainable anti-TB multi-drug delivery.10–12 Carbon nanotubes (CNTs), as biocompatible polymers, are known for the capability of high drug loading, stable release, and significant diffusion in the body.13 Therefore, the importance of CNTs has been recognized in the pharmaceutical industry.12,14,15 Multi-wall carbon nanotubes (MWCNTs), as drug carriers, should first be functionalized to enhance the biological function. Induction of carboxyl and chlorine on MWCNTs could increase the carrying capacity and reduce the complications symptoms on healthy cells.16 Moreover, timely detection and the right administration of the appropriate antibiotics could enhance the ability to recover. In contrast, aging, being infected with HIV, and having a history of TB, are some factors which make the treatment more complex.17 The focus of this research is on the preparation of the new nano product by chemical reactions, which may be classified in the nano-drug family. There has been no detailed study of the targeting INH with CNT at a dose much lower than the usual therapeutic dose. Therefore, this lower dose could reduce the side effects of the drug during the treatment. Rajarajeswari et al,18 used single-wall CNTs as carriers of INH to state that this binding could enhance the efficacy of the drug. However, they did not study the microbial and did not determine the appropriate dose. In the antibacterial effect study section, the growth inhibition zone is measured based on the amount of antibacterial substance usage.19 In this investigation, it has been attempted to confirm the antimicrobial effectiveness of conjugated MWCNTs nanofluid on M.tb by esterification reactions. Also, the prepared nano-drug was validated by the techniques such as elemental analyses of total nitrogen, hydrogen, carbon and sulfur (CHNS), Raman spectroscopy, Fourier transform infrared (FTIR), transmission electron microscopy (TEM), and scanning electron microscopy (SEM).20,21
Preparation of INH and MWCNTs
4-pyridinecarboxylic acid hydrazide, INH, with CAS-No: 54–853 (Merck, Germany) and MWCNTs (United States Research Nanomaterials, USA) were prepared.
Functionalization of MWCNTs
Functionalized CNTs were prepared by the use of acylation reactions.22,23 For carboxylation of MWCNTs, 1.5 g of MWCNTs was combined with 20 mL of sulfuric acid and nitric acid at a ratio of 3:1 for 30 min in the ultrasonic device and was replaced in reflux system for 24 h at 45 ° C. Subsequently, 100 mL of and were added to the previous phase at a ratio of 4:1, and again, placed to the ultrasonic device for 30 min.24 The reaction mixture was centrifuged, the precipitate was separated, and the supernatant was centrifuged again by adding deionized water. After several steps of washing with the solvents at the pH up to 6, the sample was washed with methanol. The solution was filtered through a 0.2 μm polytetrafluoroethylene filter, and the black solid was dried under vacuum at room temperature. For acylation of carboxylated MWCNTs, 1 g of MWCNTs with 20 mL of thionyl chloride (Merk, Germany) was mixed at 60 °C for 14 h in the reflux system. The final product was washed and separated with tetrahydrofuran (Merk, Germany) and acetone; then, it was dried in an oven at 70 °C.
For loading INH on CNT, 3 g of INH and 1 g of the chlorate MWCNT powder with 50 mL of dimethylformamide (DMF) solution were refluxed at 50, 60, and 70 ° C for 36 hours.25 The solution was extracted with tetrahydrofuran, methanol, and ethanol (96%), and then the precipitate was dried at room temperature.
Elemental analysis of C-H-N-S and FT-IR were conducted to ensure the binding of INH and CNTs.26 SEM and TEM observations were done on the functionalized nanotubes and nanotubes alone. Followed that, Raman spectroscopy was performed for MWCNTs compared to their drug conjugated form.27–29
In this step, 0.2 g of Nano-drug powder, 6 mL of 96% ethanol, and 0.06 g of Arabic gum were added to 100 mL of deionized water, and the mixture was stirred for 20 min.30 In the next step, the solution was placed in an ice container; then, sonication was carried out for 20 minutes at 200 W.
Two M.tb strains, H37Rv as standard, and S (sensitive to INH) were prepared from the microbial bank of the Mycobacterium and Pulmonary Research Department, Pasteur Institute, Iran. The S strain, separated from a sputum sample of TB patient, was sensitive to INH. Afterward, the microbial suspensions were prepared at 0.5 McFarland and were cultured in Lowenstein-Jensen (LJ) culture medium. Then different dilutions (1/2, 1/4, 1/8, 1/16, 1/32) from the first concentration (2mg/mL) of the MWCNT-drug complex were provided and were added for each strain and tested twice for each sample. The bacterial growth was assessed within three weeks; after this time, the final results were observed. Two repetitions for each sample which were treated by INH alone with a concentration of 2mg/mL were been used as controls.
Table 1 exhibits the elemental analysis to ensure the binding of INH to the MWCNTs. Indeed, MWCNTs have no nitrogen mass, but it could be measured in functionalized nanotubes, which indicates the binding of INH to MWCNTs.
Table 1 Elemental Analysis of Conjugated MWCNT
Fourier Transform Infrared
A comparison was made between the infrared spectrum of carboxylated nanotubes (Figure 1) and the infrared spectrum of the nanotubes functionalized with INH (Figure 2). Similar results with previous studies31,32 were recorded. As shown in Figure 1, the peak at 1527 is related to the C = C bond in the wall of MWCNTs. Also, the peak at 3304 cm−1correspond to the carboxylic acid group. The FTIR spectrum of INH-MWCNTs (Figure 2) confirmed the formation of amide groups on the MWCNTs surface. The peaks at 16781173 cm−1 were assigned to amide bond between the drug and nanotubes. The peak at 1603 cm−1 peak is related to the amide bounding of the pyrimidine ring of the isoniazid drug. The peaks at 743684 cm−1 are also related to the vibrations of the pyridine ring of the drug.
Figure 1 The infrared spectrum of carboxylated nanotubes.
Figure 2 The infrared spectrum of nanotubes functionalized with INH.
Scanning Electron Microscopy Data Analysis
This analysis was conducted to demonstrate the evidence for the functionalization of MWCNTs by the SEM method. Figure 3 is related to the SEM images of the MWNT–COOH, and Figure 4 exhibits the nanotubes functionalized with INH.10 The MWCNT–COOH (Figure 3) has a smooth surface. The changes in the morphology for MWCNT- INH (Figure 4) are significant. A uniform tubular layer is observable on the surface of the MWCNT (the rough part). It seems that the diameter in MWCNT- INH is slightly increased in comparison to those of MWCNT–COOH.
Figure 3 SEM image of the raw MWCNTs.
Figure 4 SEM images of MWCNTs functionalized with INH.
Transmission Electron Microscopy
The TEM images of MWCN modified with COOH and MWCNT modified by INH are given in Figure 5A and B, respectively. As it is clear in both samples the mean diameters of MWCNT are in rang of 15–20 nm. The MWCNT-COOH seemed to be a bundle or a rope of MWCNT; while, the dissociation of the bundles was observed in the MWCNT-INH. Functionalization prevented the MWCNT to aggregate in the form of bundles and enhanced their dispersibility. So, the MWCNT-INH showed a higher and more facile dispersion, in solvents, than that of the MWCNT-COOH.
Figure 5 The TEM images of the MWCNT-COOH (A) and the MWCNT-INH (B) (The red arrows indicate the diameters).
Raman Spectra Analysis
Raman spectroscopy could be a powerful tool, used to provide structural information about MWCNT–COOH, before and after functionalization. As shown in Figure 6, the D and G bands of the MWCNT, are at around 1330 and 1590 cm. A and B were observed for MWCNT–COOH, and MWCNT– INH. The increase in the intensity of the defect mode at 1330 cm is related to the sp3 hybridization of carbon, which is used as evidence of the disruption of the aromatic system of π electrons by the attached molecules.
Results of Microbial Tests
The results of the study on the effects nano-drug on two strains of M.tb (S and H37Rv) are shown in Figures 7 and 8, and Table 2. The results showed that nano-drug was completely effective on H37Rv strain and inhibited bacterial growth in the least dilution of 1/32 from the concentration of 2 mg/mL. The effect of the drug on the S strain is also noticeable since it has completely stopped the bacterial growth at dilution of 1/8 from the concentration of 2 mg/mL. As shown in Figures 7 and 8 the two repeated control samples of both S and H37Rv have been grown for untreated samples were considered as a control sample.
Table 2 Bacterial Growth Results in Different Dilutions of INH and INH Nano-Drug, Growth (+) and Non-Growth (-)
Figure 7 Sensitive strains of M.tb, treated with serial dilution (1/4, 1/8, 1/16, 1/32) of the nano-drug from the concentration of 2 mg/mL (No growth of bacteria was observed from the dilution of 1/8).
Figure 8 H37Rv strains of M.tb, treated with serial dilution (1/4, 1/8, 1/16, 1/32) of the nano-drug from the concentration of 2 mg/mL (No growth of bacteria was observed from the dilution of 1/32).
Conclusions and Future Perspective
In this investigation, a new formulation of the INH nano-drug was developed by using MWCNTs, which had a significant antibacterial effect in the low dosages, in comparison with INH alone. This nano-drug has more potential such as better penetration to the bacterial membrane, increased yields at the lower concentrations than the usual therapeutic doses, and decreased bacterial resistance toward the usual form of antibiotics. This study aimed to obtain the appropriate dose of the nano-drug, to increase the level of antibacterial function of INH. In this study, using INH nano-drug significant success in treatment was achieved at a lower concentration of nano-drug compared to the usual (1/16 for S and 1/32 for H37Rv). Finally, it was concluded that the functionalization of MWCNTs with INH would have distinct advantages such as overcoming antibiotic resistance. Several studies demonstrated the possibility of using CNTs as a nanocarrier for TB drug delivery and were conducted to overcoming on antibacterial resistance of TB.15,28 One study in 2019 reported that chitosan-functionalized CNTs could increase the drug permeability of INH in the treatment of TB in the bone and wound tissues.33 Also, Barros et al,34 demonstrated the efficacy of naphthoimidazoles together with INH and rifampin, as the main drugs for controlling tuberculosis. Also, success studies reported targeted delivery of rifampicin to TB-infected macrophages and also controlled delivery and tissue regeneration of TB. To date, this study has been performed to evaluate the efficacy of nano-drugs in comparison with the drug alone and also evaluation of drug delivery potential of MWCNTs. To use it effectively, more studies are needed, especially optimizing the method of drug conjugation, as well as more cellular and molecular studies to identify the mechanisms of its effects on bacterial growth.
The authors have no conflict of interest.
1. Bullo Saifullah MZBH, Al Ali SHH. Controlled-release approaches towards the chemotherapy of tuberculosis. Int J Nanomedicine. 2012;7:5451. doi:10.2147/IJN.S34996
2. Organization, W.H. Global tuberculosis report 2014. (World Health Organization); 2014.
3. Erwin ER, et al. Pharmacokinetics of isoniazid: the good, the bad, and the alternatives. Tuberculosis. 2019;116:S66S70. doi:10.1016/j.tube.2019.04.012
4. Tafazoli S, Mashregi M, O’Brien PJ. Role of hydrazine in isoniazid-induced hepatotoxicity in a hepatocyte inflammation model. Toxicol Appl Pharmacol. 2008;229(1):94–101. doi:10.1016/j.taap.2008.01.002
5. Saifullah B, et al. Development of a biocompatible nanodelivery system for tuberculosis drugs based on isoniazid-Mg/Al layered double hydroxide. Int J Nanomed. 2014;9:4749.
6. Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J. 1996;9(10):2026–2030. doi:10.1183/09031936.96.09102026
7. Sumartojo E. When tuberculosis treatment fails. Am Rev Respir Dis. 1993;147(1311):e20. doi:10.1164/ajrccm/147.5.1311
8. Hegeto LA, et al. In vitro combinatory activity of piperine and anti-tuberculosis drugs in Mycobacterium tuberculosis. Tuberculosis. 2018;111:35–40. doi:10.1016/j.tube.2018.05.006
9. Jagadeb M, Rath SN, Sonawane A. In silico discovery of potential drug molecules to improve the treatment of isoniazid-resistant Mycobacterium tuberculosis. J Biomol Struct Dyn. 2019;37(13):3388–3398. doi:10.1080/07391102.2018.1515116
10. Amarnath Praphakar R, et al. Phosphorylated κ‐carrageenan‐facilitated chitosan nanovehicle for sustainable anti‐tuberculosis multi drug delivery. Chemistry Select. 2017;2(24):7100–7107. doi:10.1002/slct.201701396
11. Yuan X, et al. Mucoadhesive guargum hydrogel inter-connected chitosan-g-polycaprolactone micelles for rifampicin delivery. Carbohydr Polym. 2019;206:1–10. doi:10.1016/j.carbpol.2018.10.098
12. Praphakar RA, et al. Silver nanoparticle functionalized CS-g-(CA-MA-PZA) carrier for sustainable anti-tuberculosis drug delivery. Int J Biol Macromol. 2018;118:1627–1638. doi:10.1016/j.ijbiomac.2018.07.008
13. Sheikhpour M, Golbabaie A, Kasaeian A. Carbon nanotubes: a review of novel strategies for cancer diagnosis and treatment. Materials Sci Eng. 2017;76:1289–1304. doi:10.1016/j.msec.2017.02.132
14. Praphakar RA, et al. Fabrication of bioactive rifampicin loaded κ-Car-MA-INH/Nano hydroxyapatite composite for tuberculosis osteomyelitis infected tissue regeneration. Int J Pharm. 2019;565:543–556. doi:10.1016/j.ijpharm.2019.05.035
15. Praphakar RA, et al. A mannose-conjugated multi-layered polymeric nanocarrier system for controlled and targeted release on alveolar macrophages. Polym Chem. 2018;9(5):656–667. doi:10.1039/C7PY02000G
16. Zhao B, et al. Synthesis and characterization of water soluble single-walled carbon nanotube graft copolymers. J Am Chem Soc. 2005;127(22):8197–8203. doi:10.1021/ja042924i
17. Karo B, et al. Isoniazid (INH) mono-resistance and tuberculosis (TB) treatment success: analysis of European surveillance data, 2002 to 2014. Eurosurveillance. 2019;24. doi:10.2807/1560-7917.ES.2019.24.12.1800392
18. Rajarajeswari M, et al. Functionalized single-walled carbon nanotube (5, 0) as a carrier for isoniazid a tuberculosis drug. Int J Comput Mater Sci Eng. 2015;4(03):1550014. doi:10.1142/S2047684115500141
19. Praphakar RA, Munusamy MA, Rajan M. Development of extended-voyaging anti-oxidant linked amphiphilic polymeric nanomicelles for anti-tuberculosis drug delivery. Int J Pharm. 2017;524(12):168–177. doi:10.1016/j.ijpharm.2017.03.089
20. Praphakar RA, et al. Zn 2+ cross-linked sodium alginate-g-allylamine-mannose polymeric carrier of rifampicin for macrophage targeting tuberculosis nanotherapy. New J Chem. 2017;41(19):11324–11334. doi:10.1039/C7NJ01808H
21. Neelgund GM, Oki A, Luo Z. Antimicrobial activity of CdS and Ag2S quantum dots immobilized on poly (amidoamine) grafted carbon nanotubes. Colloids Surf B Biointerfaces. 2012;100:215–221. doi:10.1016/j.colsurfb.2012.05.012
22. Shao-Yu C, Ji-Lie K. Advance in research on carbon nanotubes as diagnostic and therapeutic agents for tumor. Chinese J Analytical Chem. 2009;37(8):1240–1246. doi:10.1016/S1872-2040(08)60125-5
23. Tran PA, Zhang L, Webster TJ. Carbon nanofibers and carbon nanotubes in regenerative medicine. Adv Drug Deliv Rev. 2009;61(12):1097–1114. doi:10.1016/j.addr.2009.07.010
24. Singh RP, et al. Vitamin E TPGS conjugated carbon nanotubes improved efficacy of docetaxel with safety for lung cancer treatment. Colloids Surf B Biointerfaces. 2016;141:429–442. doi:10.1016/j.colsurfb.2016.02.011
25. Kim MJ, et al. Electrospun poly (vinyl alcohol) nanofibers incorporating PEGylated multi-wall carbon nanotube. Synth Met. 2010;160(1314):1410–1414. doi:10.1016/j.synthmet.2010.04.020
26. Jain AK, et al. Carbohydrate-conjugated multiwalled carbon nanotubes: development and characterization. Nanomedicine. 2009;5(4):432–442. doi:10.1016/j.nano.2009.03.001
27. Praphakar RA, et al. Targeted delivery of rifampicin to tuberculosis-infected macrophages: design, in-vitro, and in-vivo performance of rifampicin-loaded poly (ester amide) s nanocarriers. Int J Pharm. 2016;513(12):628–635. doi:10.1016/j.ijpharm.2016.09.080
28. Azizian J, et al. Enviromentaly friendly functionalization of carboxylated shortend multi-wall nanotubes with sunset yellow dye. Oriental J Chem. 2012;28(1):115. doi:10.13005/ojc/280117
29. Azizian J, et al. Functionalization of carboxylated multi-wall nanotubes with derivatives of N1-(11H-Indeno [1, 2-b] quinoxalin-11-ylidene) benzene-1, 4-diamine. J Chem. 2013.
30. Stefanovic J, et al. Synthesis, characterization, and antifungal activity of nystatin—gum arabic conjugates. J Appl Polym Sci. 2013;127(6):4736–4743. doi:10.1002/app.38084
31. Singh BP, et al. Solvent free, efficient, industrially viable, fast dispersion process based amine modified MWCNT reinforced epoxy composites of superior mechanical properties. Adv Mater Lett. 2015;6(2):104–113. doi:10.5185/amlett.2015.5612
32. Do Amaral Montanheiro TL, et al. Effect of MWCNT functionalization on thermal and electrical properties of PHBV/MWCNT nanocomposites. J Mater Res. 2015;30(1):55–65. doi:10.1557/jmr.2014.303
33. Chen G, et al. Isoniazid-loaded chitosan/carbon nanotubes microspheres promote secondary wound healing of bone tuberculosis. J Biomater Appl. 2019;33(7):989–996. doi:10.1177/0885328218814988
34. Barros LPC, et al. Anti-Mycobacterium tuberculosis activity of naphthoimidazoles combined with isoniazid and rifampicin. Tuberculosis. 2018;111:198–201. doi:10.1016/j.tube.2018.06.015
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.